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Abstract 
Valo, H. (2012) Biopolymer-Based Nanoparticles for Drug Delivery 
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pp. 50  
 
ISBN 978-952-10-7851-4 (Paperback), ISBN 978-952-10-7852-1 (PDF), ISSN 1799-7372 
Nanotechnology can be used to modify drug delivery by various approaches. Bio-
polymer-based nanoparticles represent a well-established option to formulate drug delivery 
systems. New therapeutic compounds are often insoluble or poorly soluble in water, which is 
a major factor in causing irregular and insufficient absorption, and reduced bioavailability of 
the drug. Increased dissolution rate can be achieved by decreasing the particle size to 
nanometer range. Another common reason for the reduced efficacy of the therapeutic 
compounds is their poor delivery to the desired site of action. Advanced nanoparticle 
formulations can be used to provide controlled release profiles or they can be combined with 
ligands for targeted drug delivery. Considering the current needs to produce stable 
nanoparticle systems for the controlled and actively targeted drug release, the versatile group 
of biopolymers may offer these functionalities.  
One topic of this work was to set-up the electrospray apparatus for the production of 
poly(lactic acid) (PLA) drug nanoparticles. By utilizing electrospray, it was possible to 
produce spherical drug-loaded PLA-particles with approximately 200 to 800 nm diameters. 
The main benefits of the electrospray method were to control the particle size as well as the 
possibility to entrap both hydrophobic and hydrophilic drugs into the polymeric 
nanoparticles.  
Second topic of this work was to utilize amphiphilic proteins, hydrophobins, to provide 
a layer around the drug nanoparticles that can be functionalized by protein engineering 
techniques. Adsorption of the protein onto the particle surface restricted the particle growth 
after the nanoparticles were formed, and it also produced a layer around the hydrophobic 
drug that was possible to functionalize further. Hydrophobin-mediated nanoparticle 
synthesis was a fast and effective process that was also easy to up-scale.  
As third topic, nanofibrillar celluloses (NFCs) from various origins were studied as 
alternative biopolymer carriers for drug nanoparticles. The nanostructured cellulose matrix, 
an aerogel, prevented the aggregation of the hydrophobin coated nanoparticles during the 
freeze-drying and storage. Controlled drug release applications could be designed and 
enabled by utilizing the various modifications of NFC matrices.  
As a result of this thesis, knowledge about the versatile biopolymer-based materials was 
provided as a means to construct stable nanoparticle formulations that can offer versatile 
applications for pharmaceutical nanotechnology. 
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1 Introduction 
Recent trends have shown that a considerable number of lead optimization compounds 
suffer from low aqueous solubility or are even completely insoluble in water.[1] These 
compounds are included in the Biopharmaceutics Classification System (BCS) classes II and 
IV and they represent about 70-90% of the drugs in the pharmaceutical industry pipelines.[2, 
3] If the poorly soluble drug candidate has reasonable membrane permeability (BCS class II), 
the drug dissolution is the rate-limiting step for absorption. Thus, low solubility causes 
irregular and delayed absorption, which may finally result in reduced bioavailability of the 
drug. On this account, the dissolution properties of the drug have far-reaching effects and, 
therefore, innumerable methods and formulations have been invented to overcome the 
problem. The improvement of drug solubility can be realized by modifications such as by 
formation of salt complex [4], pro-drug [5, 6], co-crystals [7], or by hydrates, solvates or 
amorphous forms [8-10]. 
Reduction of the particle sizes down to a sub-micron range utilizing different 
techniques has been seen as a potential answer to the dissolution problems for some time.[2, 
3, 11-13] As described by the Noyes-Whitney equation [14], dissolution rate can be increased 
by increasing the reactive surface area by decreasing the particle size. Smaller drug particles 
have been shown to further improve the bioavailability.[11] In general, synthetic or mechanic 
pathways to reach the smaller particle sizes have been divided into top-down and bottom-up 
approaches. Several comprehensive reviews including both top-down and bottom-up 
methods concerning particle engineering processes have been written.[15-17]  
Besides the particle size reduction methods, many advanced drug delivery platforms 
have been developed to obtain more precisely controlled and localized drug release that could 
significantly enhance the therapeutic effect of a drug. The most common ones, all with their 
own properties, strengths, and weaknesses are cyclodextrins [18,19], emulsions and 
microemulsions [20, 21], lipid carriers [22, 23], silicon- and silica-based nano-systems [24, 
25], dendrimers [26] as well as nanoparticles based on polymer carrier systems [27-30] just 
to mention some examples.  
In this thesis, polymer-based nanoparticles made of very diverse and versatile groups of 
biodegradable polymers have been taken into consideration as advanced drug delivery 
systems. As demonstrated, the small size without a doubt improves dissolution rates and in 
vivo bioavailability. However, challenges still exist. One of the main problems in nanoparticle 
engineering is to maintain the stability of the primary particles since otherwise the 
advantages of the small particle size are lost. 
Physical instabilities are the major challenges with the colloidal nanoparticle systems 
and typically surfactants and/or polymers are used to stabilize the nanosuspensions. In this 
thesis, assemblies of biopolymer-based nanoparticles were studied to complete functional 
pharmaceutical formulations as well as to resolve post-processing and long-term storage 
challenges for the used methods and excipients. The most commonly used excipients suffer 
from the fact that they are not able to stabilize the formulation indefinitely, stabilization 
effect might be lost e.g. during the drying process, or during the storage.[31, 32] The current 
and new stabilizers and surface modifiers are often acting as non-active excipients employed 
purely to maintain the physical stability of nanoparticles. However, apart from the size, 
surface properties are key factors controlling the in vivo fate of the nanoparticles. Indeed, the 
surface is a first part that interacts with the components of the surrounding physiological 
medium and epithelia/tissues. Thus, nanoparticles with a precise drug delivery goal, whether 
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localization or controlled release, need to show very well defined surface properties.[33] 
Surface modifiers can bring a more active functional role in targeting, permeation as well as 
sustained/controlled release of the drug.  
As a summary of the above mentioned facts, the main idea of this thesis was to prepare 
biopolymer-based nanoparticles that increase or control the dissolution rate and also the 
bioavailability of the drug compounds. Further, nanoparticles with functional coating layer 
around the hydrophobic drugs provide a way to improved stability and targeting of the 
system. These complex nanostructured compositions may offer versatile tools for the 
development of more sophisticated drug delivery systems to exceed obstacles faced by the 
conventional formulations. 
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2 Literature review 
2.1 Nanoscale drug delivery systems 
2.1.1 Particle size 
According to the definition of nano, pharmaceutical nanoparticles are considered as 
submicron-sized drug crystals, particles or drug delivery vehicles, also known as 
nanocarriers. In general, colloidal dispersions or dry solid particles with dimensions in the 
range from 10 nm to a few hundred nanometers are preferred depending on the therapeutic 
target and purpose. In addition to the therapeutic nanocarriers, other micro- and 
nanostructured materials can be potentially beneficial for the engineering of composite drug 
delivery applications. 
In pharmaceutical technology, the particle size reduction has been used as a powerful 
tool to enhance the oral administration of poorly-soluble drug compounds. Biopharmaceutics 
Classification System (BCS) divides the drugs into four classes according to their solubilities 
and intestinal permeabilities.[34] Low aqueous solubility and high intestinal permeability are 
the characteristics of BCS Class II poorly-water soluble drugs. Thus, low solubility may 
strongly restrict the absorption of the drug resulting in incomplete bioavailability.  
Accordingly, the dissolution rate is the rate-limiting step which determines the bioavailability 
of the BCS class II drugs. Reduction of the particle size leads to exponential increase of the 
number of molecules on the surfaces of the particles. Thus, an increased surface area of the 
system leads to increased surface interactions with particles’ surroundings improving e.g. 
dissolution to gastrointestinal fluids. Therefore by decreasing the particle size the dissolution 
rate can be increased.  The important factors for the kinetics of drug dissolution rate can be 
expressed by the Noyes-Whitney equation [14] (1), 
)( bs CC
h
DA
dt
dm
     (1) 
where the rate of mass transfer of drug (solvate) particles into a solvent (dissolution 
rate) (dm/dt) is dependent on the surface area available for dissolution (A), the diffusion 
coefficient of the drug (D), the thickness of the boundary layer of the dissolving drug (h), the 
saturation solubility of the drug (CS) and the concentration of the drug at particular time 
point in the dissolution medium (Cb). After administration, physicochemical factors have a 
strong influence on the factors shown in Eq. (1). Improved dissolution rate and maximized 
amount of soluble drug available for absorption are commonly realized due to the particle 
size reduction. Kawabata et al. (2011) have reviewed that, for example, nanocrystal 
formulations have been found to show 1.7–60-fold maximum plasma concentrations (Cmax) 
and 2–30-fold increases in area under the plasma concentration-time curves (AUC), after 
oral administration compared to crystalline formulations with micrometer particle size.[11]  
Apart from the enhanced dissolution of the poorly-soluble drug compounds by size 
reduction, another goal in designing pharmaceutical nanoparticles is to control the drug 
delivery in order to release pharmacologically active agents at the therapeutically optimal 
rate and site. [2, 31, 35-37] Nanocarriers, like polymer-based nanoparticles composed of 
advanced materials, can offer possibilities to control and sustain the drug release, leading to 
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improved pharmacokinetic and pharmacodynamics (PKPD) properties or lowered toxicity. 
After administration, unmodified free drug compounds are widely distributed throughout the 
body affecting other organs than the desired tissues or cells. Therefore, the doses of the drugs 
are often limited due to the adverse side effects at the expense of efficient treatment.[38] 
2.1.2 Surface modification 
Modification of the nanocarrier surface properties can be utilized to increase the 
residence time in the blood.[39] If an intravenously administered particle does not dissolve 
immediately, blood proteins are adsorbed onto its surface resulting in recognition by the 
immune system (opsonization). The particles are then taken up by the mononuclear 
phagocyte system (MPS), which leads to fast clearance from blood circulation. Delays in 
opsonization [40] can be achieved either by the adsorption of polymers or surfactants on the 
surfaces of the nanocarriers (non-covalent attachment) or by covalent attachments of 
molecules onto the surfaces. One of the most widely utilized strategies is adsorption or 
grafting of poly(ethylene glycol) (PEG) molecules on the nanocarrier surface.[41] For 
example, steric PEG coating increased the half-life of bovine serum albumin (BSA) loaded 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles from 13.6 min to 4.5 h.[42] Apart from 
hydrophilic coatings (e.g. PEGylation), adjusted surface charges of the nanocarriers may play 
a significant role in the body.[43] It has been widely shown that nonspecific cellular 
internalization and protein adsorption during the circulation can be affected by changing the 
surface charge.[43, 44] Positively charged nanoparticles have higher rates of phagocytosis 
compared to neutral or negatively charged formulations, resulting in shorter blood 
circulation half-lifes.  
Encapsulation of sensitive drug molecules into particulate nanocarriers can protect 
them against degradation in vitro and in vivo, but may also offer more patient friendly 
administration routes. Polymeric nanoparticles can be highly beneficial for delivering and 
protecting biologically active entities, such as proteins and peptides, as well as RNA and DNA 
therapeutics.[45] Enzymatic and hydrolytic degradation can be delayed by encapsulation or 
coupling of these molecules with nanocarriers, and thus, protecting them against elimination 
in vivo. For example, various nanotechnological carriers based on polymeric materials have 
been developed to enable the oral administration of insulin.[46] 
Nanocarriers, nanosized compositions of drugs and polymer, may enable specifically 
targeted or passively localized drug delivery.[47] For example, the use of nanocarriers as drug 
delivery vehicles for anticancer therapeutics are based on the enhanced permeability and 
retention (EPR) effect at the tumor site, due to the particular physical properties of tumors, 
such as leaky blood vessels and poor lymphatic drainage.[48-51] With the small size and the 
hydrophilic surfaces, the nanocarriers tend to increase the residence time in blood, which 
facilitates the passive accumulation (targeting) to the tumors.[52] Another example of the 
localized release systems is drug delivery to mucosal surfaces, such as gastrointestinal tract, 
nose, eyes, lungs or the female reproductive system.[37, 53] A mucoadhesive polymer coating 
of particles may interact with the mucous surface, leading to an increased residence time in 
close contact with the mucosa and also to an increased drug stability against digestive 
enzymes.[54-56]  
Active targeting can be reached for example by functionalization of the nanocarriers’ 
surface with specific targeting moieties, such as antibodies [57], receptor binding molecules, 
peptides [58], proteins [59] and saccharides [60, 61], in order to deliver the therapeutic 
compound to specific cells, tissues or organs.[62, 63] For example, human serum albumin 
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nanoparticles coupled to transferrin or transferrin receptor monoclonal antibodies enabled a 
significant loperamide transport across the blood-brain barrier against the transferrin 
receptor in the brain.[64] Overall, due to the more advanced and targeted methods, systemic 
toxicity of the medical treatments can be reduced by using nanoparticles or carriers. 
2.2 Preparation methods for drug nanoparticles 
Several strategies are available to improve the therapeutic performance of low-soluble 
drug compounds. To date, no single method or material has emerged as an ideal solution. 
Examples of these approaches and production methods with their advantages are listed in 
Table 1. Production methods can be classified into the top-down and bottom-up approaches. 
Top-down methods involve size-reduction of larger particles to the nanometer level. The 
most commonly used top-down methods are wet milling and high pressure homogenization, 
which have resulted in a few commercial products.[12, 65, 66] 
In contrast to the top-down techniques, in bottom-up methods the nanocarriers are 
synthesized starting from the molecular level in a solution based on self-assembly. 
Conversion of the dissolved molecules into nanodispersed system is accomplished by 
precipitation or condensation.[67] In spite of the similar principles, the spectrum of the drug 
nanocarriers made by the bottom-up methods is wide.  
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Table 1 Examples of nanoscale drug delivery approaches. 
Nanocarrier 
system 
Production 
method 
Advantages  
 
References 
Lipid based 
nanocarriers 
liposomes, 
niosomes, 
microemulsions, 
solid lipid 
nanoparticles 
Formed by 
phospholipids 
dispersed in 
water. The lipid 
core is stabilized 
by surfactants.  
Biocompatible and biodegradable.  
Suitable for both hydrophilic and 
hydrophobic drugs.  
Avoidance of organic solvents. 
Size, charge, and surface 
functionality can be modified. 
Established liposomal products on 
the market.   
[68-71] 
Polymeric 
/polymer- based 
nanoparticles 
 
Electrospray, 
Precipitation, 
Salting out, 
Aerosol flow 
reactor methods, 
Spray drying, 
Double-
emulsification 
High surface modification capacity. 
Applicable for versatile materials. 
Possibility to load and stabilize a 
large range of organic or biological 
molecules. The drugs can be released 
in a controlled manner; through 
surface or bulk erosion, by diffusion 
through the polymer matrix, swelling 
followed by diffusion, or in response 
to the local environment. 
 
[72-74] 
Porous silicon- and 
silica-based nano-
systems 
Porous particle 
production by 
electrochemical 
etching and 
milling. Drug 
loading by 
immersion of the 
PSi particles or 
layers into the 
loading solution. 
Applicable for loading and 
stabilization of a large range of 
organic or biological molecules.  
Solid dosage form.  
Release profiles can be controlled 
due to the pore size and functional 
groups. 
Carriers can be produced with near 
monodispersity. 
[75, 76] 
Nanocrystals 
(colloidal 
dispersions of drug 
crystals, stabilized 
by surfactants or 
polymers) 
Wet milling. 
High pressure 
homogenization. 
Cost-effective method. 
High drug loading. 
Scalable. 
Low batch-to-batch variation. 
Simple to perform.  
Solution and solid dosage forms.  
Avoidance for organic solvents. 
Established products on the market.   
 
[3, 66, 77, 
78] 
Cyclodextrins Drug-
cyclodextrin 
complex 
formation. 
Kneading, 
Co-precipitation,  
Freeze-drying, 
Spray-drying. 
Enhanced stability of therapeutic 
molecules.  
Taste masking (reduced bitterness).  
Established products on the market.   
 
[18, 79] 
In spite of the versatile and specific advantages, each delivery system has its limitations 
e.g. instability of the drug and/or carrier, polymorphic changes of the drug, low drug 
entrapment efficiency, difficulties in controlling size and polydispersity of the nanocarriers, 
as well as burst and/or uncontrolled drug release. Furthermore, each production method has 
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drawbacks, such as the need of organic solvents, high batch-to-batch variation and up-
scaling, which provide challenges for translating these delivery or production methods for the 
industrial use.[22, 51, 67, 80, 81] More detailed challenges related to the preparation of 
biopolymer-based drug nanoparticles are presented in chapter 2.4. 
Due to the versatile characters of various polymers and production methods, 
therapeutic molecules can be entrapped, attached, dissolved or encapsulated into the 
polymer matrices.[33] Depending on the structural composition of the drug and polymer, 
they can be classified, e.g., to nanospheres and nanocapsules having different morphologies, 
properties and drug release characteristics. Nanospheres consist of matrix type structures 
and nanocapsules are vesicular systems, in which the drug is surrounded by a single 
polymeric membrane. In general, the term “nanoparticle” has been used to cover these 
systems. Depending on the preparation method and used biopolymer, the latter can perform 
a role as a passive colloidal stabilizer or also alternatively as an active substance having a 
significant role in the nanoparticle synthesis and bioavailability. Some bottom-up methods 
are based on self-assembly of the polymers, lipids and surfactants, while the others require 
some processing equipment.  Both types of methods are represented in this thesis in detail, 
the electrospraying method and solvent-antisolvent precipitation method, respectively. 
2.2.1  Electrospraying  
The phenomenon behind the electrospraying (electrohydrodynamic atomization) has 
been known since the 19th century, but it was not until 1914 when John Zeleny [82] 
demonstrated fine droplet formation from a conical shaped meniscus, which was followed by 
innumerable experimental works, before the method became popular. The interest towards 
electrospraying has caught on multidisciplinary applications after the Nobel Prize work by 
Fenn on mass spectroscopy (2002).[83] 
In the technique of electrospray, electric field is used to produce very fine droplets of 
charged liquid out from a thin capillary nozzle. A sufficient electric field between the liquid 
and counter electrode causes the accumulation of charges on the surface of the liquid. When 
the potential difference is sufficient, the electrostatic forces overcome the surface tension, the 
surface becomes unstable and the meniscus develops a conical shape [84]. If the cone is then 
disturbed by a further charge, it will break into small charged droplets which will detach from 
the liquid cone and fly towards a counter electrode. Several different spraying modes exist 
(Figure 1) [85, 86], but for the production of monodisperse nanosized droplets the cone-jet 
mode is the most desired, known as a Taylor cone [84, 87].  
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Figure 1 Different geometrical forms of liquid meniscus A) cone-jet (Taylor cone), B) 
dripping, C) micro-dripping, D) spindle, E) multi-jet, F) multi-spindle, G) 
ramified-meniscus. Modified from reference [86]. 
The droplet size and size distribution are controllable to some extent. Several variables, 
such as liquid properties, conductivity, flow rate, surface tension and viscosity, affect the 
properties of the end product, but e.g. flow rate and conductivity ratio should be fixed in 
order to obtain a stable spray.[88, 89] Overall, the stable cone-jet mode can be attained 
within a rather narrow range of flow rates and voltages. During the process, the solvent 
evaporates from the highly charged droplets and the droplets start to shrink, which also 
hinders the coalescence of the droplets with the same charge sign.  
Electrospray generated by an electrostatic atomization has been applied in numerous 
studies in many disciplines [90, 91] including the synthesis of polymeric drug micro- and 
nanoparticles.[90, 92-94] Table 2 lists examples of recent studies of polymeric drug micro- or 
nanoparticles produced by the electrospray.  
Table 2 Recent studies of polymeric drug micro- or nanoparticles prepared by 
electrospray. 
Polymer Particle size Therapeutic molecule / References 
Poly(lactic-co-
glycolic acid) 
(PLGA) 
0.6-1.4 μm  
0.2-1.2 μm  
0.1 -2.5 µm  
5–10 μm 
0.2-0.9 μm 
Doxorubicin, rhodamine[95] 
Budesonide[96] 
Oestradiol[97] 
BSA and lysozyme[98, 99]  
Paclitaxel [100] 
Poly(lactic acid) 
(PLA) 
3-4.5 μm BSA[101]  
Chitosan 0.3-0.9 μm   
0.5 μm  
Doxorubicin[102]  
Ampicillin[103] 
Elastin-like 
polypeptides 
0.3−0.4 μm Doxorubicin[104] 
Poly-caprolactone 
(PCL) 
1-15 μm Taxol[105] 
Nanoparticles with controlled size and narrow size distribution can be produced by 
dissolving the polymer and drug into a sufficiently conductive solvent capable of being 
electrosprayed. The solvent evaporates during the flight of the droplets towards a ground 
electrode. At some point, the driving force for crystallization/precipitation of the solute takes 
over causing particles to form, which can be collected from a liquid, gelatinizing bath or 
surface. Attaining the desired particle size, size distribution and morphology might be 
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challenging with this method. The right parameters have to be experimentally found for each 
case and the correct instrumentation set-up used.  
Electrospraying is a suitable method for molecules that do not process well because it 
does not induce dissociation of the molecules. For example biological materials have been 
electrosprayed without changing the biological activity.[106] Other benefits of the 
electrospraying are simplicity and a possibility for continuous one-step production processes. 
With electrospray ionization, it is possible to process small amounts of materials without 
extensive losses. The method also enables water-insoluble and soluble drugs to be combined 
into a single nanoparticle. 
2.2.2 Solvent-antisolvent precipitation  
Antisolvent precipitation method is scalable bottom-up method to form drug 
nanoparticles.[107] Two miscible solvents are required. The drug is dissolved in the first 
solvent (e.g. organic solvent) and then added to the anti-solvent solution (e.g. water). 
Precipitation/crystallization is based on the formation of a supersaturated state of the drug 
due to the mixing of the solvent and the antisolvent, which results in a fast nucleation rate 
leading to the production of particles. Particle or crystal habits may be affected by lowering 
the surface energy by the adsorption of different additives, such as surfactants or polymers at 
growing interfaces of the solids.[108-112] Recently, modifications of the concept have been 
carried out in order to form variously structured nanoparticles. Examples of nanoprecipitated 
formulations are listed in Table 3. Overall, in this method and its variants, optimization of the 
supersaturated state and the growth and morphology of the particles can be affected, by 
controlling parameters like temperature, agitation, and antisolvent-solvent composition and 
ratio.[113-115] The nucleation rate is highly dependent on the supersaturation. Therefore, 
higher supersaturation state due to lower temperature and strong homogenizing mixing 
result in smaller particles, because a larger number of nuclei are formed.[116] 
Table 3 Recent studies of drug micro- or nanoparticles prepared by 
polymer/surfactant assisted solvent-antisolvent precipitation. 
Polymer/ 
Surfactant 
Particle size Therapeutic molecule / References 
Poloxamer/polyvinylpyrrolidone 0.2-0.5 µm Danazol, naproxen [108] 
Hydroxypropyl methylcellulose 3.6 µm Beclomethasone dipropionate [109] 
Hydroxypropylcellulose 5 µm Siramesine hydrochloride[110] 
Hydroxypropyl methylcellulose 0.1-0.3 µm Triclosan [112] 
2.3 Biopolymers as excipients 
Numerous synthetic and natural polymers have been extensively investigated as 
polymeric materials for drug delivery applications. To be considered as a suitable material to 
deliver drugs in vivo, a polymer needs to fulfill several requirements.[117] Firstly, it needs to 
be biocompatible and the possible degradation products should not be toxic or immunogenic. 
Secondly, the material should still have acceptable long-term stability and it should allow 
processing procedures required during the formulation. For the first reason, natural 
biodegradable polymers have been introduced as platforms and as stabilizing agents of 
nanoparticles for several drug nanoparticle formulations. 
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Natural polymers such as cellulose and its derivatives [118, 119], chitosan [120],  
alginate [122], albumin [123], gelatin [124, 125], and starch [121] and starch derivatives like 
cyclodextrins and polylactides [126], are widely available in nature and constitute an 
important class of biopolymers for immobilization of biological and chemical entities.  
Biosurfactants are an alternative to the common natural polymers.[127] Biosurfactant 
is a general term for compounds that are produced by microorganisms, either extracellularly 
or as a part of the cell membrane, by bacteria, yeasts and fungi, having pronounced surface 
and emulsifying activities due to the amphiphilicity.[128, 129] Most biosurfactants comprise 
of hydrophobic moieties consisting of saturated, unsaturated, or hydroxylated fatty acids, or 
fatty alcohols, together with an anionic/cationic or neutral hydrophilic moiety containing 
mono-, oligo- or polysaccharides, peptides, or proteins. They are often secondary metabolites 
of microorganisms having essential functional role for the host biological functions and 
survival in the environment.[130-132] In addition to the surface activity, properties such as 
biodegradable nature, low toxicity and degradation to non-toxic end products in an aqueous 
environment, high tolerance to extreme pH-values, temperature and ionic strength and 
antimicrobial activity, make them very useful for many applications.[133] Recently, proteins’ 
multifunctionality, biodegradability and uniform characters have been studied in food 
technology [134], and for drug delivery purposes [59, 135] and therapeutic applications. A 
typical protein surfactant is e.g. fungal hydrophobin, an amphiphilic protein from 
Trichoderma reesei.[136, 137]  
Some of the inherent or refined properties of polymeric biomaterials that can affect to 
their biocompatibility, biodegradation, drug entrapment and release, as well as processing, 
include crystallinity, chemical structure, molecular weight, solubility, 
hydrophilicity/hydrophobicity, water absorption, degradation and erosion mechanisms. The 
interactions, affinity and influence of the drug with the polymeric material have also an 
impact on nanoparticle formulation and functionality.[138, 139]  
2.3.1 Hydrophobins 
Hydrophobins are a group of proteins identified first from Schizophyllum commune 
[140] and lately related to filamentous fungi more widely.[141, 142] Hydrophobins are 
secreted to surroundings or retained in the fungal structures, involving fungal development 
in many stages dominated by the surface activity and surfactant-like properties.[143, 144] A 
adsorbed hydrophobin films enable the growth of fungal aerial hyphae, formation of 
protective structures, and mediate the attachment of fungi to solid surfaces.[140, 145, 146]  
Hydrophobins can be considered safe for human use because of their presence in e.g. 
common button mushrooms, Agaricus bisporus and fungus-fermented food.[137, 147] 
Hydrophobins can reduce immune recognition of airborne fungal spores by masking the 
surface layer and, hence, prevent immune response.[148] On the other hand, they may also 
act in pathogenic infections by mediating the attachment into the host organism.[149] 
Traditionally, hydrophobins have been divided into two classes (referred to as Class I 
and II) on the basis of differences in amino acid sequences and their hydropathy patterns and 
also based on the aqueous solubilities of their assembled forms.[150] Both classes have 
conserved eight cysteine residues in their amino acid sequences, but otherwise the sequences 
between and within the classes are heterogeneous. Class I hydrophobins (e.g. SC3) form 
aggregates and assemblies which can be only dissociated by using strong acids like 
trifluoroacetic acid and formic acid.[151] Although, class II hydrophobins (e.g. HFBI, HFBII) 
form monomers, dimers and tetramers depending on their concentration, they are highly 
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soluble in water, even at concentrations over 100 mg ml-1..[152] The secondary structure of 
class II hydrophobins, HFBI and HFBII, does not change during the adsorption at the 
interface. This can also explain the faster self-assembly of class II hydrophobins leading also 
to a faster reduction in the water surface tension.[153-155] Recently, it has been shown that 
the strict allocations of many of the identified hydrophobins to either class I or class II is not 
clear [156] and there are few species that coexpress both hydrophobin classes.[157, 158]  
The tertiary structure of hydrophobins deviates from the conventional; the hydrophobic 
side chains on the surfaces are prevented from turning inside the protein (Figure 2). Thus, 
instead of the hydrophobic interactions, the protein core is stabilized by the network of the 
disulfide bonds.[137] Due to this character, the hydrophobin molecule is amphiphilic, owing 
hydrophilic and hydrophobic parts like ordinary surfactants. Hydrophobins are one of the 
most surface active biomolecules and they have been widely studied for their unique surface 
adhesion properties. Although all hydrophobins adhere to surfaces, there is a difference in 
their binding characteristics. E.g. Class II hydrophobin HFBI managed to compete in binding 
efficiency with class I hydrophobin SC3, but was more easily dissociated than class I 
hydrophobin, whose adherence was stronger.[155]  
 
Figure 2 Structure of HFBI. Hydrophobic batch is shown in green. Modified from 
[154]. 
The unique natural features of hydrophobins, as well as recombinant technology can be 
used to modify hydrophobin sequences to have desired or improved properties for a wide 
range of applications.[137, 159, 160] Hydrophobins can act as tags for purification of 
recombinant fusion proteins by aqueous two-phase separation.[160] HFBII has an ability to 
produce exceptionally stable foams.[161, 162] The ability to act as emulsifiers [146] and 
foaming agents is beneficial to many applications, but on the other hand, having 
hydrophobins in the products, can cause harm to the beverage industry, such as the gushing 
of beer.[163] Class I hydrophobin SC3 has been used to formulate suspensions of 
hydrophobic drug compounds for oral drug administration.[164] The SC3 hydrophobin was 
used to reduce the particle size to microns and increase the bioavailability of two 
hydrophobic drugs, nifedipine and cyclosporine A.  
Furthermore, hydrophobins can be genetically modified to gain benefits such as 
adhesion on target surfaces. Binding to cellulose could be mediated via cellulose binding 
domains (CBDs), which are the non-catalytic part of the cellulose and hemicellulose 
degrading enzyme.[165, 166] Recently, the cellulose-binding function of hydrophobin (HFBI) 
was obtained by a fusion with two cellulose-binding domains (CBDs) to bring nanofibrillar 
cellulose in a controlled manner to different interfaces.[167]  CBDs interact with cellulose via 
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hydrophobic interactions of three aromatic amino acids on one face of the molecule.[168-
170].  
2.3.2 Poly(lactic acid) 
Polyesters, including Poly(lactic acid) (PLA), the linear polymer composed of lactic acid 
monomers, have attracted much attention as pharmaceutical and medical systems (Figure 3). 
PLA monomers exist in two optically active isomers; Poly(L-lactic acid) (L-PLA) and poly(D-
lactic acid) (D-PLA).[171] The physicochemical properties, such as melting points and partial 
crystallinity of the optically active isomers, are nearly equal. The polymer composed of 
racemic mixture of monomers may have very different characteristics than its monomers.  
PLA has favorable physicochemical characteristics, like high mechanical strength, 
compatibility with a wide range of tissues, and a biodegradable nature showing no 
immunogenicity.[172] Depending on the type of degradation, polymeric biomaterials can be 
further classified into hydrolytically degradable and enzymatically degradable polymers. 
Hydrolytically degradable polymers have hydrolytically labile chemical bonds in their 
backbone. The presence of esters, a functional group susceptible to hydrolysis, allows 
hydrolytic degradation of PLA.[173] The susceptibility for hydrolytic degradation is a two-
sided characteristic due to the undesired effect during processing and storage, but 
advantageous to the function of the drug formulation in the body. The hydrolytic degradation 
rate is primarily affected by the exposition to an elevated temperature and humidity, 
although other parameters like the degree of the crystallinity, morphology (porosity), 
molecular weight and environment (pH, ionic strength) have an effect on water uptake, 
which must be considered when the degradability is assessed.[174] Depending on these 
variables, the degradation time can vary from several hours up to years.[175] For example, 
the rate of degradation decreases with an increase in crystallinity, because the amorphous 
structure allows water to penetrate to the structure; resulting in a faster degradation.[44, 176] 
PLA is commercially available in different compositions and molecular weights, which allow 
the control of the polymer degradation.[175] In the body, PLA degrades via the citric acid 
cycle, finally forming innocuous metabolites water and carbon dioxide.[177] Therefore PLA is 
also a USA Food and Drug Administration (FDA) approved material. 
PLA has received much attention as a renewable raw material; l-lactic acid can be 
produced in large-scale from plant sources by fermentation.[177, 178] Polymeric PLA can be 
synthesized either by a direct condensation of the lactic acid or by ring-opening 
polymerization (ROP) of the lactide. From direct condensation, the resultant polymer is a low 
to intermediate molecular weight material. In the catalytic ROP, molecular weight of the PLA 
can be controlled and it also enables polymers with higher molecular weights and lower 
polydispersities. Furthermore, ROP allows the preparation of block copolymers and, 
therefore, the ROP is often the most preferred.[174, 179]   
 
Figure 3 Poly(lactic acid) polymer.  
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Due to the favorable features like biodegradability and biocompatibility, PLA and its 
copolymers are one of the most used biodegradable polymers for coatings [74, 180, 181] and 
matrix materials in drug delivery systems.[182] 
2.3.3 Nanofibrillar celluloses  
Cellulose is the most abundant and renewable natural polymer on the earth. 
Inexhaustibility, biocompatibility, high stiffness and strength as well as possibilities for a 
wide variety of derivative products make cellulose optimal for numerous applications 
including functional pharmaceutical formulations. The cellulose polymer consists of linear 
β(1-4) linked anhydro-D-glucose units repeated as dimers, called cellobioses (Figure 4). Each 
glucose unit has three hydroxyl groups attached to the ring.  
 
Figure 4 The repeat unit of cellulose, dimer called cellobiose. [183] 
The parallel straight cellulose chains are present in lamellae or bundles called 
microfibers. The formation of microfibers occurs via van der Waals forces and both 
intramolecularly, by the interaction between OH-groups in the same molecule, or by 
intermolecularly with the other cellulose chains, bundling the chains together.[184, 185] On 
plant cell walls, the microfibers are further embedded in combination with hemicelluloses 
(such as xylan), lignin, and other minor substances (such as pectin), further forming 
macrofibers and resulting in complex morphologies despite the cellulose’s apparent chemical 
simplicity. Xylan is a polysaccharide made from xylose units and including functional 
carbonyl groups. Thus, the surface charge of native cellulose develops as a result of the 
deprotonation of the carboxyl groups found in hemicellulose.[186]  
 Recently, individual cellulose fibers (referred to e.g. as nanofibrillar cellulose, 
nanocellulose, microfibrillated cellulose, NFC etc.) and crystals (referred to e.g. as cellulose 
nanocrystals, whiskers) with nanometer widths, extracted from wood and plant sources or 
from bacterial cultures, have gained increasing attention. For comprehensive reviews, please 
refer to.[183, 187-189] Apart from plants, algae, certain bacteria strains and marine tunicates 
are also known to synthesize cellulose.[190] Typically nanofibrillar cellulose (NFC) is 
generated from cellulose microfibers by mechanical treatments consisting of refining and 
high-pressure homogenization combined with pretreatment processes like alkaline, oxidation 
treatments or enzymatic hydrolysis (Figure 5).[187, 191, 192]  
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Figure 5 Three methods to disintegrate macroscopic cellulosic fibers into nanoscale 
fibrils or crystals. Reprinted with permission from [191]. Copyright 2011 
American Chemical Society. 
The mechanical properties, hydrophilicity, crystallinity, degree of polymerization and 
the success of the disintegration process of fibrils, strongly depend on the source, extraction 
and other treatments of the native cellulose.[185] Due to the high aspect ratio (~100-400), 
fibers are very susceptible to the interactions with surroundings and other molecules 
containing functional groups, such as water, solvents or nanoparticles that can form 
hydrogen bonds. The strong bonding of hydroxyl groups between the individual polymer 
chains makes cellulose water insoluble but provides the capability for chemical modification 
to obtain specific functionalities.[193]  
Differences in the molecular orientations and in the network of hydrogen bonds causes 
the ordered regions of cellulose to exist in several polymorphs (forms I, II, III, and IV and 
their allomorphs).[189] In natural fibers, cellulose occurs mainly in the crystalline form I 
(divided into allomorphs Iα and Iβ) mixed with amorphous regions.[194] 
Drying of the untreated cellulose can cause a phenomenon called hornification, 
meaning that cellulose can lose some of its accessibility and reactivity, and the redispersion of 
fibrous cellulose material is prevented because of irreversible aggregation of the fibrils.[195] 
Surface modifications, such as 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO)-mediated 
oxidation of the primary alcohol group at C6 in cellulose molecule, has been used to minimize 
the adhesion caused by interfibril hydrogen bonds before the mechanical disintegration 
treatment to gain mostly individualized cellulose nanofibrils and also to prevent 
aggregation.[196, 197] When the primary hydroxyl groups are oxidized to carboxylic salts by 
TEMPO-mediated oxidation [197], anionic functionalities are provided to the surface of the 
microfibrils.[198] Thus, the repulsive effect of the charged surface enhances the separation of 
individual microfibrils.[186]  
In long nanofibrillar cellulose, the aspect ratio is high and, therefore, it can be used in 
order to form porous structures that can act as templates for nanoparticles in stabilization 
and drug delivery purposes. Nanofibrillar celluloses have been used to make aerogels either 
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by itself [199] or in composite formulations, wherein porous NFC templates have formed 
magnetic [200] or electrically conducting flexible aerogels [201], or aerogels with tunable 
oleophobicity [202]. Porous structure with a larger surface area of aerogels can interact and 
prevent the aggregation of the nanoparticles more efficiently compared to the conventional 
microcrystalline cellulose.[186, 203] 
Various bacteria, such as a genus of Gluconacetobacter strains, fermentate cellulose in 
high yields (up to 40%) using glucose as a substrate.[188, 204] Bacterial cellulose (BC) has 
the same molecular formula as the celluloses derived from plant materials, but have a high 
water holding capacity, tensile strength and crystallinity (80-90%).[205, 206] Accompanying 
substances, such as hemicelluloses and lignin, present in plant cellulose are missing from BC 
and, therefore, no harsh chemical treatments are needed to purify the BC.[207] It has been 
shown that various cultivation parameters, substrates, additives and bacterial strains have 
strong influence on the physicochemical properties of the produced cellulose, such as molar 
mass and homogeneity.[207-209] Bacterial cellulose has been shown to be a remarkably 
versatile biomaterial for example in food packaging applications [210], paper products [211], 
electronics [212], and medical devices [213]. 
2.4 Stability of biopolymer-based nanoparticles 
One of the main problems in nanoparticle engineering is to maintain the stability of the 
primary particles since otherwise the advantages of the small particle size are lost. The 
surface of a material has an excess energy compared to the bulk. Due to the decreased 
particle size and increased surface area, the nanoparticles tend towards more 
thermodynamically stable state driven by an increased free energy. Thus, without sufficient 
stabilization, the aggregation of nanoparticles in media will occur soon after the particle 
formation, and at least during long-term storage. Nanoparticles have high particle mobility 
due to the Brownian motion and, thus, the particles collide with each other. The probability 
of particle-particle interactions increases with smaller size. If the particles are not sufficiently 
stabilized, they may aggregate. The irreversible aggregation of the particles following by 
quality problems such as the sedimentation of the colloidal system are related to these 
interparticle forces. According to the DLVO-theory [214, 215], solid particles are exposed to 
attractive van der Waals forces and repulsive forces due to the electrostatic double-layer. 
Aggregation occurs when the attractive forces exceed the repulsive electrostatic forces. 
However, the theory can only be used to describe the relevance of electrostatic interactions in 
colloids, but does not extend or explain other “non-DLVO forces” such as hydrophobic 
interactions or steric repulsion.[216-218]  
In colloids, the stabilization against irreversible aggregation can be realized by using 
steric (physical barrier) and/or electrostatic stabilization (surface charge) on the surface of 
the nanoparticles.[31] Ionic or non-ionic surfactants and polymers have been commonly used 
to provide a barrier against the aggregation of nanoparticles.[65, 112] Steric stabilization can 
be attained by covering the particles by polymers which prevent the particles’ access to the 
range of attractive forces by forming a physical barrier. Furthermore, a non-ionic amphiphilic 
polymer/surfactant with a hydrophobic chain around the hydrophobic drug surface allows a 
hydrophilic part to project into the water and, thus, also increase its hydrophilicity. Steric 
interactions are more sensitive to temperature fluctuations than electrostatic repulsion.[31] 
In contrast, ionic stabilizers are very sensitive to changes in pH and ionic strength, and are 
also incapable of stabilizing nanoparticles in the dry state.[32]  
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Electrostatically and/or sterically stabilized particles can still move, and thus their 
agglomeration is just hindered by the prevalence of thermodynamic repulsive forces.[219] 
The kinetic stabilization can be improved by increasing the viscosity of the liquid, for 
example by the formation of a polymer network using e.g. xanthan gum [219] Overall, when 
selecting a stabilizer, it has to be recognized as safe for administration, it must wet the 
surface of poorly water-soluble compounds, and it should withstand the post-processing of 
the formulation, e.g. drying or sterilization.[13, 66] 
The long-term storage of nanoparticles in suspensions presents many disadvantages, 
such as the risk of microbiological contamination, premature polymer degradation by 
hydrolysis, physicochemical instability due to the particle aggregation, sedimentation and 
chemical instability of the drug. To avoid such problems, dry formulations are preferred over 
the suspensions. In general, the transformation of a liquid preparation into a dry product can 
be achieved using sensitive drying methods such as freeze-drying [203, 220] or spray-drying 
processes [221].  
Polymorphism is common for pharmaceutical solids; they may exist in more than one 
crystalline solid form. Polymorphic transitions take place easily both during the particle size-
reduction processes, post-processing and the storage. The crystalline material has a specific 
three-dimensional structure, in which molecules are arranged in a regular manner. In 
contrast, amorphous material has no regular three-dimensional long-range order, but may 
still have a short-range order, which is present over several molecular dimensions.[222] 
Production process can cause that crystalline solid to turn completely into an amorphous 
solid form. Polymers are typically semicrystalline, they contain both amorphous and 
crystalline regions. In addition, in the nanoparticle formation process, water or organic 
solvent molecules can be incorporated in the crystal structure. Depending on the solvent type 
in the crystal lattice, such crystals are known as hydrates or solvates. However, the high 
energy and molecular mobility also make amorphous solids physically unstable during the 
long-term storage. Furthermore, during the formulation processing, the polymer and drug 
may have interactions with each other.  
Aggregation of the nanoparticles as well as polymorphism has notable impact on the 
dissolution rate. Therefore, changes in these may affect the therapeutic efficacy of the 
pharmaceutical formulation.[223] Amorphous substances are more soluble than their 
crystalline counterparts, and hydrates show slower dissolution compared to anhydrous 
forms. Therefore, solid state characterizations are required for both nanosuspensions and dry 
nanopowders.[222] Aggregation of the particles can be estimated by electron microscopy 
techniques or by observing phenomena related to light scattering. The appropriate tools for 
solid state analysis include X-ray techniques (XRPD, WAXS) and thermal analysis (DSC). 
Thermal events like melting, as well as the changes in diffraction patterns, can be used to 
detect transformations in the solid state. Variability in the dissolution rates caused by 
aggregated nanoparticles and polymorphic changes can result in unpredictable variations in 
drug delivery and bioavailability.[203, 224, 225]  
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3 Aims of the study 
The purpose of this study was to find new nanotechnological ways to produce and 
stabilize biopolymer-based drug nanoparticles, for controlled drug release or improved 
solubility and bioavailability of drug compounds with low water-solubility. The nanoparticles 
were produced with two different techniques, electrospray and nanoprecipitation methods. 
The performance of the particles was evaluated utilizing 1) different solid state 
characterization methods, 2) dissolution studies, as well as 3) in vivo bioavailability tests. 
Nanofibrillar celluloses from five different origins and with versatile characteristics were 
introduced as nanoparticle carriers and matrix formers for controlled drug delivery. 
Specifically, the goals were as follows: 
 
 Set-up of the electrospray method for the production of homogenous 
biopolymer-based drug nanoparticles. The specific target was to control the 
particle characteristics, such as size and morphology with process variables.  
 Preparation of functionalized protein-coated drug nanoparticles by using 
genetically modified hydrophobin proteins. The specific aim was to obtain 
particle surfaces that could be further tailored by modifying hydrophilic side of 
the hydrophobins via protein bioengineering. 
 Use of hydrophobin proteins in combination with both native and chemically 
modified nanofibrillar cellulose (NFC) to facilitate storage and post-processing 
of nanoparticles. The specific aims were to formulate dry nanoparticle powders 
and to improve the stability of drug nanoparticles and to control the dissolution 
rate of drug nanoparticles via optimized characteristics of NFC aerogels.  
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4 Experimental 
Complete experimental details can be found in the original publications (I-IV). 
4.1 Materials                       
The model drug compounds were beclomethasone dipropionate (BDP) (Sigma, St, 
USA), salbutamol sulfate (SS) (Orion Pharma, Finland) and itraconazole (ITR) (Apotechnia, 
Spain). Itraconazole (Sigma-Aldrich, USA), hydroxyl-itraconazole (OH-ITR) and 
itraconazole-d5 (Toronto Research Chemicals Canada) were used as references in in vivo 
experiments. Poly(L-lactic acid) (PLA) (MW 2000g mol-1, ICN Biomedicals Inc., USA) was 
used for the formation of nanoparticles by electrospray. Microcrystalline cellulose (MCC) 
(Avicel PH101, FMC International, Ireland) was used as a reference to nanofibrillar celluloses 
(NFCs) (IV). The production, purification and conjugation processes of the used cellulose 
materials and hydrophobins are described in publications listed in Table 4 and Table 5 with 
corresponding publication references. Green fluorescent Protein (GFP), Double Cellulose 
Binding Domain (DCBD) 
Table 4 Hydrophobins (HFBI, HFBII) and HFBI fusions with Green Fluorescent 
Protein (GFP) and Double Cellulose Binding Domain (DCBD) used in this 
work. 
Compound References Publications 
HFBII [226] II 
GFP-HFBI [227] II 
HFBI [226] III-IV 
HFBI-DCBD [160] III-IV 
Table 5 Nanofibrillar celluloses used in this work. 
Compound References Publications 
Native wood (birch) cellulose  
UPM-Kymmene 
Corporation[228] 
III 
Bacterial cellulose VTT[229] IV 
Quince seed cellulose VTT[230] IV 
TEMPO-oxidized wood cellulose VTT[197] IV 
Red pepper cellulose  
The University of 
Tokyo 
IV 
4.2 Methods                          
The equipment used in the experiments and characterization are summarized with 
references to the corresponding publications in Table 6. 
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Table 6 Equipment used in this study. 
Method Publication Equipment/Manufacturer 
Electrospray apparatus I Home-constructed system: Power supply (UTK 
Microfluidic Toolkit, Micralyne, Edmonton, 
Canada), CCD camera (Watec WA-502A), syringe 
pump (Harvard Apparatus Pump 5, Playmouth 
Meeting, PA, USA) 
UV-spectrophotometer I Ultrospec III, Pharmacia (LKB Biotechnology,  
Sweden) 
Scanning electron 
microscopy (SEM) 
I DSM 962, (Zeiss, Jena, Germany),  
Photon correlation 
spectroscopy (PCS) 
I Zetasizer 3000HS (Malvern Instruments, 
Worcestershire, UK) 
Modulated temperature 
Differential scanning 
calorimetry (MT-DSC) 
I-IV DSC 823e and STARe Software (Mettler-Toledo, 
AG, Switzerland).  
Freeze-dryer II-IV Kinetics Thermal Systems Lyostar II, (SP 
Industries Inc., Warminister, USA) 
Variable temperature X-
ray powder 
diffractometry (VT-
XRPD) 
I-IV Bruker AXS D8 advance, (Bruker AXS GmbH, 
Germany) 
Transmission electron 
microscopy (TEM) 
I-IV Fei Technai F12, (Philips Electron Optics, The 
Netherland) 
High Pressure Liquid 
Chromatography  
(HPLC) 
II-IV Agilent 1100 Series (Agilent technologies, Santa 
Clara, CA, USA) 
Fluorescent Microscope II Olympus BX-50. Emission light was filtered with 
a WG Filter (510-550 nm) 
Liquid Chromatography-
Tandem Mass 
spectrometry (LC-
MS/MS) 
III Agilent 6410 Triple Quadrupole mass 
spectrometer Technologies (Palo Alto, CA, USA) 
Ultrasound bath I-IV GWB Branson 3200, (Danbury, USA) 
Dissolution apparatus 
(small scale) 
II, IV Sotax AT7 (Perkin-Elmer Lambda 2, Germany) 
Dissolution apparatus 
(large scale) 
III Erweka DT-6 (Heusentamm, Germany) 
 
Atomic force microscope 
(AFM) 
IV A NanoScope IIIa Multimode (E-scanner, Digital 
Instruments/Veeco), NSCI5/AlBS cantilever 
(µMASCH) 
Fourier transform 
infrared spectroscopy  
(FTIR) 
IV Bruker Optics Inc., MA, USA 
Horizontal Attenuated Total Reflectance (ATR) 
(MIRacle, Pike Technology, Inc, WI, USA) 
Wide angle x-ray 
scattering (WAXS) 
IV Custom build (SAXS/WAXS) x-ray camera. Cu-
anode x-ray tube monocromatized with 
multilayer optics (Montel). WAXS intensity was 
measured with MAR345 image plate detector. 
4.2.1 Electrospraying 
A schematic diagram of the electrospray equipment used in the production of 
nanoparticles is shown in Figure 6. The sprayed solution was fed by a syringe pump (Harvard 
Apparatus Pump 5, Playmouth Meeting, PA, USA) and syringe needle (Hamilton, USA) at a 
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flow rate of 2-10 µl min-1 through a silica capillary (outer diameter 0.10 mm, inner diameter 
0.05 mm) to a receiving beaker. During the experiments a cone-jet mode was monitored by a 
CCD camera (Watec WA-502A). The solution was sprayed at an applied voltage of 1–8 kV 
(UTK Microfluidic ToolKit, Micralyne, Edmonton. Canada). Working electrode was 
connected to the needle with alligator clips. Grounded counter electrode was a copper wire 
wrapped around the collection beaker. The distance between the needle tip and the surface of 
the receiving solution was kept at 3-5 cm. In some experiments a nitrogen flow was used to 
enhance the evaporation of the organic solvent during spraying.  
Conductivity of the spraying liquid was controlled by adding 0.02-0.20% ammonium 
hydroxide in 96% ethanol. Set-up A: Ammonium hydroxide was included to the sprayed 
liquid and only nitrogen gas was fed through a nozzle outside of the capillary (Figure 6). Set-
up B: The nitrogen gas and the organic salt solution (pumped at flow rate 3.0-8.2 µl min-1) 
were fed through a T-part connected to the spraying liquid at the end of the silica capillary. 
 
Figure 6 Illustration of the electrospray system (set-up A) used for the production of 
encapsulated drug nanoparticles. Modified from publication I. 
4.2.2 Solvent-antisolvent precipitation 
Nanoparticles were prepared by using a simple bottom up method, nanoprecipitation 
(II-IV) (Figure 7). In this anti-solvent precipitation method, the hydrophobic drug was 
dissolved in an organic solvent. Tetrahydrofuran was used as a solvent for itraconazole (ITR) 
and methanol for beclomethasone dipropionate (BDP). Amphiphilic proteins HFBI, HFBII or 
HFBI-DCBD were first dissolved in water (0.6 mg/ml) and the solutions were sonicated and 
placed on an ice bath. Before use, the ITR and BDP solutions (12 mg/ml) were filtered with 
0.2 µm PVDF or GHP syringe filters (PALL, Ann Arbor, MI, USA) to remove possible dust 
particles. Then, the ITR or BDP solutions were rapidly added into the hydrophobin solution. 
The receiving liquid was stirred vigorously with a magnetic stirrer and temperature of the 
solution was controlled by keeping the sample on ice. A white precipitate was observed as a 
turbid solution immediately after the ITR addition, indicating the formation of the 
nanoparticles. 
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Figure 7 Schematic illustration of the hydrophobin assisted solvent-antisolvent 
precipitation of hydrophobic drug. 
4.2.3  Binding to cellulose nanofibrils 
After precipitation, the nanosuspensions were stirred for 20 min to evaporate the 
residuals of organic solvent. Then the cellulose nanofibrils or microcrystalline cellulose 
(MCC) in water were added to the nanosuspensions and incubated under mild stirring for  
45 min. 
In the formulations with different nanofibrillar celluloses (wood cellulose (1.66% 
hydrogel) bacterial cellulose (0.3% hydrogel), TEMPO-oxidized cellulose (0.8% hydrogel) 
from quince seeds (0.12% hydrogel) or from red pepper cellulose (dry) and microcrystalline 
cellulose (dry), the amount of cellulose was expressed in terms of dry weight. The ratio of 
drug: HFB: cellulose nanofibrils of 1:1:2 was used in all the experiments (III, IV).  
Regenerated cellulose tubular membrane MWCO 3500 (CelluSep, Spectrum Labs, San 
Antonio, USA) was used to remove residuals of the organic solvents from the nanoparticle 
suspensions if the particles were used for in vivo animal studies (III). The dialysate was 
ultrapurified water and was changed after 2 and 6 hours during a total dialysis time of  
14 hours.  
For the removal of water, the suspensions were frozen with liquid nitrogen (II, IV) 
or/and immediately placed into a freeze-drying chamber (Kinetics Thermal Systems Lyostar 
II, SP Industries Inc., Warminster, USA ) (III). ITR particle dispersions were dried on the 
freeze-dryer with or without NFC and D±trehalose (TRE). BDP particles were dried with or 
without NFC. The ratio of ITR:TRE was 1:1.25. Exact details of the freeze-drying cycles are 
described in corresponding publications (II-IV). 
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4.2.4 Characterization  
Sizes and size distributions of the PLA-nanoparticles were determined with dynamic 
light scattering (I). Particle sizing was based on the photon correlation spectroscopy (PCS); 
the results were analyzed by CONTIN algorithm and the sizes presented are based on the 
intensity distributions. The width of the particle size distribution was estimated by the 
polydispersity index (PI). The PI values range from 0 (perfectly monodisperse) to 1.00 
(polydisperse particles, broad distribution), with the limit of monodisperse particles being ca. 
0.10.  
For the (MT-)DSC experiments the nanosuspensions were allowed to dry at room 
temperature (I) or freeze-dried (II-IV). Powders were weighted in aluminum pans. Runs 
were carried out in pans which were sealed with aluminum caps with pin holes.  Thermal 
behavior of the freeze-dried nanopowders was studied using a differential scanning 
calorimeter (Mettler-Toledo Inc., Switzerland). The samples were held at 25 °C for 5 min 
before heating. All the samples were heated from 25 to 250-350 °C depending on the samples 
(I-IV). The heating rate was 2-10 °C min−1. The data was analyzed with STARe software 
(Mettler-Toledo Inc., Switzerland).  
Electron microscopy studies for the nanoparticles were performed by using a scanning 
electron microscope (SEM) and a transmission electron microscope (TEM). For SEM, the 
nanopowders were either dried directly (I) or freeze-dried and then attached on the metal 
plates by using two-sided tape (IV). The plates were sputtered for 25 seconds with platinum 
prior to the SEM analysis. For TEM studies, the nanoparticle suspensions were dried or 
spread (freeze-dried powder) on Formvar film-coated copper grids with the mesh size of 300 
(Agar Scientific, Essex, U.K.). 
The labeling studies were performed for the fresh BDP-HFBII nanosuspensions. GFP- 
labeled BDP nanoparticles were studied by using Fluorescence Microscope. The synthesis of 
the nanoparticles was carried out normally, except that a part of the HFBII was replaced with 
the GFB-HFBI fusion protein. The GFB labeling of the microparticles was performed after 
the synthesis by adding GFP-HFBI to the solution containing BDP microparticles. Labeling of 
the BDP nanoparticles with the mercaptosuccinic acid (MSA) coated Au-nanoparticles was 
performed by adding MSA-Au particle solution to BDP-HFBII nanoparticles suspension (1:2) 
and incubating for 1 h before sampling. Particles were imaged by TEM. 
Samples for XRPD analysis were either dried on the silicon plates (I) or freeze-dried to 
powder form (II-IV). The experiments were performed in a symmetrical reflection mode 
with Cu Kα radiation (1.54Å) using Göbel Mirror bent gradient multilayer optics. The 
scattered intensities were measured with a scintillation counter. The angular range was from 
5◦ to 4o◦. The measurements were made with the steps of 0.02◦, and the measuring time was 
0.5-2s/step depending on the samples. In Varied Temperature (VT)-XRPD measurements, 
the samples were heated on the sample vessels at 24, 55, 90, 106, 115, 145, 180 and 220 ◦C at 
a speed of 10 ◦C/min and kept at the assigned temperatures during each measurement (II). 
Crystallinities of the samples were estimated by comparing the intensities of crystalline and 
amorphous samples (I). The reference data were retrieved from Cambridge Structural 
Database (CSD) using Conquest program.  
4.2.5 Dissolution studies 
Dissolution behaviors of the BDP nanoparticles were studied using either 40 ml of 36% 
(v/v) ethanol (BDP nanosuspensions, II) or 40 ml of 0.3% SDS (freeze-dried BDP powders, 
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IV) as a dissolution medium. The solubility of BDP in water is so low that the use of ethanol 
or surfactant in the dissolution mediums was justified for detection aspects. The temperature 
was maintained at 37 ± 0.5 °C (Sotax AT7, Perkin-Elmer Lambda 2) and the stirring rate was 
100 rpm. In the case of suspensions, a 4 ml (0.5 mg/ml) portion of cold (+4 °C) nanoparticle 
suspension was added to the dissolution media. Powders were loaded inside gelatin capsules 
(size 0). The released amount of BDP was determined by HPLC (Agilent 1100 series, Agilent 
technologies, Germany) at a wavelength of 242 nm.  
Dissolution studies of the freeze-dried ITR powders were performed immediately after 
the freeze-drying. Dissolution tests of the ITR samples were performed using a paddle type 
dissolution apparatus (Erweka DT-6, Germany) with a rotation speed of 150 rpm (III). 
Dissolution medium (400 ml) was 0.2% (w/V) NaCl-HCl pH 1.2 and the temperature was 
maintained at +37±0.5 oC.  Powders were loaded inside gelatin capsules (size 0). A theoretical 
amount of ITR was 0.5 mg in each sample. The released amount of ITR was determined by a 
HPLC (Agilent 1100 series, Santa Clara, CA, USA) at a wavelength of 261 nm.  
4.2.6 In vivo studies 
Investigations of the bioavailability of different itraconazole formulations were 
performed in University of Eastern Finland, Kuopio. Male Wistar rats were purchased from 
Laboratory Animal Center (University of Eastern Finland, Kuopio). The animals received 
intragastrically 1 mg of itraconazole/animal in one of the following formulations: 1) 
Sporanox® oral solution, 2) HFBI, 3) HFBI + NFC, 4) HFBI-DCBD + NFC or 5) itraconazole 
powder suspended in water. Blood samples were collected from the saphenous vein into 
heparinized microcapillaries (Drummond Microcaps, Drummond Scientific Co. Broomall, 
PA, USA) prior to administration and 0.5, 1, 2, 3, 5, 8, 12 and 24 h after the administration. 
The analysis of itraconazole and hydroxyl-itraconazole from plasma samples was modified 
from a previously published method.[231] National Animal Experiment Board of Finland 
approved the experiments and they were conducted in accordance with the guidelines set by 
the Finnish Act on Animal Experimentation (62/2006) and European Community Council 
Directives 86/609/EEC. 
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5 Results and discussion 
5.1 Drug nanoparticles by electrospraying (I)  
5.1.1 Preparation 
In study I, the PLA drug nanoparticles were produced by dissolving the polymer and 
drug in an organic solvent (or solvent-water in the case of hydrophilic salbutamol sulfate) 
and spraying them together. Therefore, forming of a strict core-shell structure was 
hypothetical and a matrix structure could be more descriptive for these nanoparticles. 
Factors such as the strength of the electric field, the composition, viscosity and electrical 
conductivity of the spraying liquid, changes in the liquid flow rate and the diameters of the 
silica capillary, were shown to be essential for the formation of a conical jet shape and, thus, 
eventually dictating the size of the droplets produced.[89, 234] For instance, the molecular 
weight of the used polymer has a significant influence on the particle morphology and size 
due to the viscosity.[235] Previous studies have shown that small and smooth spherical 
particles could be generated more easily from low- than higher-molecular-weight 
polymers.[100, 104, 236-238] Furthermore, in vivo PLA hydrolysis is dependent on factors 
such as polymer crystallinity and molecular weight.[239, 240] Low molecular weight PLA 
(2000 g mol-1) was selected for this study because of faster biodegradation (e.g. after 
pulmonary delivery) compared to higher molecular weight PLA (Mw above 10 000 g mol-1).  
For the production of nanometric and monodisperse polymeric particles, stable cone-
jet mode has to be formed in the spraying nozzle. In our set-ups, voltage ranges from 2.7–6.2 
kV produced a stable jet mode; otherwise the significance of the used voltage was minor 
compared to the other parameters. Previous studies have shown that electrical conductivity 
of the spraying liquid has a significant role in maintaining stable spraying conditions.[89] In 
line with the literature, in this study (I) the distinct influence of adequate electrolytic 
concentration was shown. At an optimal 0.05% ammonium hydroxide concentration, particle 
size could be controlled by changing the polymer concentration or flow rate, as is shown in 
Table 7.  
Table 7 Electrical conductivity had a significant role in having stable spraying 
conditions. Particle sizes and standard deviations (nm) of PLA-
nanoparticles prepared under different flow rates and polymer 
concentrations with ammonium hydroxide content of 0.05% and applied 
voltage 6.2 kV (n = 2-6) are shown. (I) 
 
PLA content 
Particle size (nm) at different flow rates 
4 µl min-1 6 µl min-1 8 µl min-1 
1% 280 ± 10 310 ± 60 340 ± 50 
3% 360 ± 70 450 ± 100 630± 250 
6% 550 ± 120 500 ± 60 630 ± 70 
When the physical processing parameters were adjusted together with the sprayed 
solvent properties, a stable cone-jet mode could be attained and particle sizes could be 
controlled to some extent. The right processing parameters had to be experimentally 
examined for each case. The correlations between the parameters are presented in Table 8.  
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Table 8 When the four physical processing parameters, voltage, spraying distance, 
flow rate and solvent conductivity were adjusted, a stable cone-jet mode 
could be attained. Production of monodisperse particles was attained only 
in stable cone-jet mode and particles sizes could be controlled to some 
extent. The control of the particle size and morphology could be performed 
by changing the other parameters. The arrow (↑) describes the increasing of 
the parameter. Table is reproduced with permission from [93]. Copyright 
2011 Informa Healthcare. 
Parameter Effects Product properties affected 
Solvent vapour pressure Evaporation rate of solvent Particle morphology 
Nozzle dimensions (↑) Droplet size (↑) Particle size (↑) 
Polymer MW (↑) Viscosity (↑) Particle size (↑) and 
morphology 
Polymer concentration (↑) Viscosity (↑) Particle size (↑) and 
morphology 
Molecular weight of the used polymer and its concentration in the solution has 
influence on the particle size and morphology due to viscosity.  For example the particle size 
was increased with increasing polymer concentration and flow rate (polymer–drug ratio was 
kept at a constant level of 10:1). The mean particle sizes could be adjusted between 200 nm to 
800 nm by controlling the parameters during the spraying. Polydispersity indices obtained 
from the photon correlation spectroscopy (PCS) showed moderate size deviations (PI 0.1-0.5) 
and the nanoparticles were generally spherical with smooth surfaces. Solvent evaporation 
plays an important role in the mechanism of electrospraying and particle formation. During 
the process, the solvent evaporates from the droplets and the droplets start to shrink, causing 
nanometer-sized particles to form. Therefore, it has influence on the structure of the formed 
particles.[100, 237] Too fast solvent evaporation can cause porous particles and slow solvent 
evaporation incomplete polymer solidification before the nanoparticles reach the receiving 
liquid. The evaporation rate could be controlled by adjusting the gas flow rate.  
In the case of hydrophilic SS, the spraying solution contained water in addition to the 
organic solvents. Therefore, a propylene glycol was used to keep the suspensions smooth 
during the processes. In addition, a surfactant was important in stabilization of the formed 
nanoparticles. Tween-80 was added to both the spraying solution and also to the receiving 
liquid. Tween-80 forms a steric layer around the precipitating polymer which prevents the 
particle aggregation. An amount of the Tween-80 in the receiving liquid influenced the size of 
the formed nanoparticles. A high concentration (0.1% v/v) of Tween-80 heavily increased the 
particle size compared to lower amounts of the surfactant (0.01–0.06% v/v). Size 
distributions were also broader, probably due to aggregated particles. Thus, the surfactant 
concentrations in the receiving solution gave the contribution to the manufacturing process 
of monodisperse nanoparticles. Furthermore, 70% ethanol as a receiving liquid was observed 
to prevent the aggregation of nanoparticles more efficiently than pure water, probably due to 
the increased miscibility of the PLA and the aqueous phase. 
5.1.2 Characterization 
The physical state of the solid poorly soluble drug is one of the most important 
characteristics together with the size affecting the stability, solubility and dissolution, and the 
bioavailability of the drug.[225] Solid state changes of the drugs and polymers are common 
both during the manufacturing process and during the storage.[242] In addition, the 
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materials used in formulations may interact with each other. Therefore, the solid state of the 
PLA nanoparticles and possible interactions with the drugs and the polymer were examined 
by using DSC and XRPD.  
The electrosprayed PLA nanoparticles were dried at room temperature for solid state 
characterization (I). In DSC thermograms, an endothermic event at around 155 °C indicated 
the melting of crystalline L-PLA (Figure 8). Generally, the process decreased the crystallinity 
of PLA due to fast solvent evaporation during the solidification of the polymer in the particle 
formation process. A crystallization of amorphous material could be seen as a small 
exothermic peak at 100 °C with the PLA-drug nanoparticle samples when compared the bulk 
PLA. The melting peak of BDP was not detected in the DSC scan. Its absence was explained 
by the miscibility of BDP in the PLA, rather than by a change into an amorphous phase 
during the manufacturing process. Further, the XRPD results confirmed the existence of 
anhydrate BDP. In contrast, a weak melting peak of SS was detected. The XRPD patterns of 
the nanoparticles included the reflections of BDP, SS and PLA. Supporting observations 
could be seen from the XRPD results: the crystallinity of materials was decreased, but no 
transformations in the crystalline forms were seen. Because no new peaks were seen in the 
DSC profiles or XRPD, there should not be strong physical or chemical interactions between 
the drugs and the polymer. 
 
 
Figure 8 A) DSC thermograms of bulk PLA powder, PLA-SS and PLA-BDP 
nanoparticles. Small exothermic events were observed at around 100 °C 
(arrows) in both PLA-drug samples. B) SEM image of PLA-SS 
nanoparticles (225 nm). (I) 
Obviously, the suitability of electrospray for both hydrophilic and hydrophobic drug 
compounds was the major advantage. In study I, the loss of drug during the electrospraying 
with salbutamol sulfate was 20%, which was caused mainly by the spreading of the particles 
to the surroundings during the process. The entrapment efficiency (EE) was used to quantify 
the amount of the drug entrapped into particles. The EE of hydrophilic salbutamol sulfate 
(SS) and hydrophobic beclomethasone dipropionate (BDP) into PLA-nanoparticles were 
more than 50%. The values revealed that the method was able to produce PLA drug 
nanoparticles with good entrapment efficiencies. For the hydrophilic substance, entrapment 
into the hydrophobic polymer is advantageous in formulation of drug delivery systems and 
improving their stability and bioavailability in the body. 
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Mild processing conditions, low temperature and normal air pressure ensures the 
suitability of the process also for sensitive therapeutic molecules. Scale-up of the electrospray 
for industrial applications may require, e.g., several spraying nozzles, which would increase 
the production costs, but a continuous process mode could be organized without major 
input.[95]  
5.2 Drug nanoparticles by precipitation (II-IV) 
5.2.1 Preparation 
Precipitation is a commonly used, well-known bottom-up method for producing 
nanoparticles. It is also easily up-scaled and even a continuous mode can be obtained.[233] 
However, as mentioned in the context with the electrospray method, the critical parameters 
such as the solvent-antisolvent ratio, stirring rate, temperature, and selection and amount of 
the stabilizer, had a major influence on the nanoparticle formation also in the precipitation 
process. Efficacy of the precipitation was determined on the basis of the amount of free drug 
in the aqueous outer phase. The BDP and ITR nanoparticles prepared by the precipitation 
method were almost completely entrapped into the nanoparticles. No or very small amounts 
of drug could be detected from the outer phase of the nanoparticles immediately after 
precipitation. Compared to electrospraying, the precipitation method with similar set-ups is 
not suitable for both hydrophobic and hydrophilic drugs. However, the phenomenon behind 
the spontaneous crystal formation is complex. Therefore each component and parameter has 
an implication for particle size, morphology and recovery rate.  
In studies II - IV spontaneous adsorption of amphiphilic proteins, hydrophobins, was 
utilized in order to restrict the crystallization and further reduction of the particle sizes. 
During the precipitation of the drug, hydrophobins self-assembled on the surfaces of the 
growing drug crystals and, finally, an adequate amount of hydrophobin inhibited the crystal 
growth completely, leading to the formation of drug nanoparticles. Therefore, the mean sizes 
of the BDP and ITR nanoparticles could be decreased to a certain level with narrow size 
distributions.  
In study II, experiments showed that size and morphology of the BDP nanoparticles 
were affected strongly by increasing the concentration of the surface active protein HFBII. In 
the case of BDP, a morphological change of the resulting particles appeared to be abrupt from 
needles to round shapes (Figure 9) (II). As for the ITR, the morphological change was not so 
dramatic (III). No additional changes in the particle sizes or shapes were observed with 
hydrophobin concentrations exceeding certain, determined levels (drug-protein ratio 1:1). By 
using the hydrophobin assisted precipitation method, homogenous and round BDP and ITR 
particles were formed.[241] At the optimum, BDP particles with diameters of 100 ± 30 nm 
and ITR particles of 100 ± 60 nm were obtained. Apart from the hydrophobin concentration, 
the optimized precipitation process consisted of a low temperature (+4◦C), high stirring rate 
and ratio of outer phase/solvent which were responsible for the advanced supersaturation 
and nucleation during the precipitation. 
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Figure 9 TEM images showing the effect of hydrophobin concentration on crystal 
habit and size of the BDP particles. BDP particles precipitated with the 
protein (HFBII) -drug ratio of a) 0:1 (pure BDP), b) 0.08:1 HFBII c) 1:1 
(II). 
5.2.2 Characterization  
The solid state of the BDP and ITR nanoparticles was analyzed after lyophilization (II-
IV). The physical state of the nanoparticles and possible interactions with excipients were 
examined using DSC, (VT-)XRPD, and WAXS. The drug needs to be dissolved for the 
precipitation, and thus it is prone to physical changes. Previously, it has been reported that 
BDP exists in an anhydrate or a monohydrate form or may form solvates with e.g. alcohols 
and halogenated hydrocarbons.[243, 244] In some previous studies BDP has been completely 
transformed into an amorphous form as a consequence of the processing.[245] Based on the 
characterization results, BDP was converted partly to a monohydrate or completely to an 
amorphous form during the precipitation. In the VT-XRPD, changes in BDP crystal 
structures were observed by heating the samples gradually to set temperatures based on the 
DSC thermograms (Figure 10).  
 
Figure 10 A) DSC thermograms of precipitated BDP (dashed line), HFBII (dotted 
line), and BDP (solid line) precipitated with HFBII. Arrows indicate the 
crystal structures based on the VT-XRPD results. B) VT-XRPD of 
precipitated BDP nanoparticles with HFBII at various temperatures. 
Reference patterns are shown at the bottom of the figures (II). 
a b c
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The second model drug ITR was partly amorphous and partly crystalline after the 
precipitation and lyophilization processes. All the precipitated nanoparticle suspensions were 
freeze-dried before further analyses and, therefore, the crystalline state was undefined 
immediately after precipitation. Overall, these characterization results indicated that the 
solid state changes of both ITR and BDP took place during the preparation of the solid 
nanoparticles. As described, BDP and ITR were at least partly amorphous after the 
preparation and the original (raw material) crystalline form of BDP was converted from an 
anhydrate to a monohydrate. Amorphous material dissolves much more easily than its 
crystalline form, but is very prone to crystallization during storage. In addition, hydrated 
crystals exhibit slower dissolution rate than their anhydrate counterparts [246] and, 
therefore, the polymorphic change may decrease the effect of the smaller particle size. 
5.3 Properties of nanofibrillar cellulose (III, IV)  
In this thesis, nanofibrillar celluloses (NFC) from different sources were harnessed for 
the colloidal stabilization or controlled drug delivery of drug nanoparticles (III, IV). The 
advantages of the thin cellulose nanofibrils included their modification capacity via both 
chemical modification and specific functionalization. The prior modification was used to 
provide carboxylic groups on the surface of the fibrils and was obtained by the TEMPO-
oxidation process. The latter method was realized using a bi-functional amphiphilic protein, 
HFBI coupled with two specific cellulose binding domains (DCBD). In this approach, one 
protein block with aromatic amino acids had affinity towards the cellulose and the other 
towards the lipophilic nanoparticles. In addition to these two, cellulose fibrils offered 
inherent sites for functionalization due to the presence of hemicelluloses (native NFC). In 
wood and plant cell walls, cellulose exist together with hemicelluloses, lignin and other minor 
components, and even after mild purification and fibrillation processes cellulose can still be 
considered as a composite structure. Thus, the adsorbed hemicellulose layer may have 
different properties according to chemical structure and amount of hemicellulose.[247, 248] 
These functional sites may offer possibilities to affect, e.g., the surface charge of the fibrils 
and, thus, increase the stability of the individual fibrils and colloidal stability of NFC 
dispersions.[186]  
The studied cellulose nanofibrils were obtained from various sources and extracted 
using different treatments methods. The studied NFC materials were characterized by AFM, 
XRPD, DSC and FTIR. The electrostatic stabilization of the fibrils was evaluated based on 
their ζ-potentials at different pH-values. Moreover, depending on the cellulose origin and 
extraction method, the fibrils characteristics, such as diameters, pIs and crystallinities, 
showed differences (Table 9).  
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Table 9 Characteristics including diameter, isoelectric point (pI), crystallinity of the 
NFC fibrils and a short description of the cake formation during freeze-
drying. (III, IV) 
NFC Diameters pI Crystallinity* Cake formation 
Bacterial cellulose  5-7 nm,  
bundles 20 nm 
3.2 High Well-formed 
TEMPO-oxidized  
wood cellulose  
3-5 nm 1.5 Low Well-formed  
Quince seed cellulose  3 nm 1.5 Very low Partially 
shrunken 
Red pepper cellulose  0.9-2.3 nm 1.5 Very low Collapsed 
Wood (birch) cellulose 5-20 nm 1.0 ND ND 
*After freeze-drying, ND = Not determined 
XRPD studies of the cellulose nanofibrils were performed in order to investigate the 
crystalline state of the freeze-dried cellulose fibrils. The XRPD pattern of bacterial cellulose 
and TEMPO-oxidized cellulose showed crystallinity which was related to the native cellulose 
crystal structure I. The bacterial cellulose had a high crystallinity compared to the other 
NFCs.  No diffraction was seen in XRPD spectrum of the red pepper or quince seed cellulose 
and, hence, an amorphous structure was assumed.  
Fourier transform infrared spectroscopy (FTIR) was carried out on the freeze-dried 
cellulose powders in order to identify the functional groups present on the surfaces of the 
cellulose fibrils. The FTIR spectra confirmed the existence of carboxyl groups, which was 
related to hemicelluloses, such as xylans in quince seed and red pepper celluloses. Also the 
specific band present in the cellulose engineered by TEMPO-oxidation was related to the 
carboxylic acid groups.  
The ζ -potential is a measure of the surface charge and is dependent on both the 
functional groups present on the surface of the fibrils and the environment, e.g., pH and ionic 
strength. The results showed strong negative charges (-50 mV) for three of the NFCs (quince 
seed, TEMPO-oxidized and red pepper) at pH 5. These originated from the deprotonated 
carboxyl groups on the fibrils. Native NFC from wood had a negative charge of -28 mV at pH 
4. In contrast, MCC and especially the bacterial cellulose had lower, insufficient charges  
(-25...-10 mV) considering colloidal stabilization via pure electrostatic interactions. Based on 
the results, the electrostatic repulsion between the fibrils is sufficient (30 mV, positive or 
negative) once the charged groups were dissociated due to a sufficiently high pH.  
5.4 Drug nanoparticles immobilized in nanofibrillar cellulose (III, IV) 
5.4.1 Surface functionalization of drug nanoparticles 
Hydrophobin coatings around the drug particles provided a site for surface 
functionalization. The protein used in the first study (II) was a class II hydrophobin HFBII. 
Class II hydrophobins, HFBII and HFBI have very similar size and behavior, and also mixed 
layers could be adsorbed on the surfaces of the particles. Therefore, nanoparticles with 
different hydrophobins could be prepared as described in Chapter 5.2.1. Because of the 
similarities between the different hydrophobins (HFBI, HFBII), HFBI could be selected for 
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further studies (II, III, IV) on the basis of its specific engineered properties. HFBI could be 
synthesized as coupled, e.g., with the double cellulose binding domains (DCBD) and with the 
green fluorescent protein-marker (GFP). After the particle formation, an existence of a 
hydrophobin layer around the solid drug nanoparticles was confirmed by using the 
fluorescent character of GFP (II). GFP-HFBI coated nanoparticles were successfully detected 
by using a fluorescence detector of a microscope.   
Furthermore, mercaptosuccinic acids (MSA)-coated Au nanoparticles (3 nm) were used 
to image the drug nanoparticles (II). The Au nanoparticles were bound to the drug 
nanoparticles via electrostatic interactions. This labeling could be used for example for the 
localization of the particles in electron microscopy or as an alternative route for surface 
functionalization, e.g., for drug or protein immobilization.[249-251].  
5.4.2 Binding to cellulose nanofibrils 
In further studies (III, IV) the cellulose-binding functionality of the nanoparticles was 
realized through a HFBI coupled with two specific cellulose binding domains (DCBD). CBDs 
interact with cellulose via aromatic amino acids organized on the surface of the protein (and 
thus on the surface of the nanoparticles). The more efficient binding capacity of the DCBD 
compared to ordinary HFBI has been proved recently.[167] Because the long term stability of 
the nanoparticles can be low, association with the cellulose network was expected to improve 
the steric stabilization of the particles. Steric stabilization can be considered as an effective 
mechanism to shelter drug nanoparticles against aggregation and degradation during the 
post-processing and in vivo conditions. It can be more effective than ionic stabilization 
because of the high ionic strength and variation in pH in the human body, and because 
electrostatic stabilization might be lost e.g. during freeze-drying. However, CBD’s specific 
binding to crystalline cellulose material may have caused also some drawbacks.[252] The 
crystallinity of the fibrils extracted from plant material was low and the fibrils were partly 
covered by hemicelluloses, which probably hindered the efficacy of specific binding in the 
thesis experiments (IV).  
The nanoparticles were mixed in suspension with the various types of nanofibrillar 
celluloses (NFC). HFBI coated BDP and ITR nanoparticles were used as controls. On the 
basis of the TEM images of the suspensions, it was found out that all the hydrophobin coated 
drug nanoparticles were well-mixed into the NFC networks (Figure 11). No external particles 
were seen in the suspensions immediately after mixing. 
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Figure 11 Immobilization of hydrophobin-coated ITR nanoparticles into nanofibrillar 
cellulose network (III). 
5.4.3 Stability studies  
The effect of pH, temperature and post-processing (dialysis, freeze-drying) on the 
stability of the hydrophobin coated BDP and ITR particles was studied. (II, III, IV). Stability 
of the BDP and ITR nanosuspensions was evaluated by imaging of the suspensions using 
TEM and SEM.  
In suspension, at pH 5, the BDP nanoparticles started to aggregate after 1.5 h, but at pH 
8 they could be stored for at least 1 week at +4 ºC (II, IV). The results could be explained by 
the increased electrostatic stabilization since due to the increased pH, the hydrophobins on 
the surface of the particles were charged. The calculated isoelectric points of the 
hydrophobins were 6.7 (HFBII), 6.0 (HFBI) and 6.7 (HFBI-DCBD). In the pH-values above 
pI, the particles were negatively charged. At room temperature, the BDP nanoparticles 
started to show morphological changes already after 24 h, despite the increased pH (IV). An 
elevated temperature accelerated the physical changes of the particles and, therefore, the 
particles were more unstable at room temperature compared to +4 ºC. In contrast to BDP 
particles, ITR nanoparticles were stable at room temperature for weeks, while in cold (+4 ºC) 
they survived stable for several months (III). They were also viable after dialysis in room 
temperature as the bioavailability studies showed.  
Since the BDP nanoparticles showed poor long-term stability in suspension and 
changes such as particle aggregates were observed, freeze-drying was introduced. According 
to the previous studies, freeze-drying is a sophisticated way to obtain powders from the 
nanosuspensions.[203, 220] Usually cryo- and lyoprotectants, such as carbohydrates (e.g. 
trehalose, sucrose or mannitol), have to be used to protect the nanoparticles against 
morphological changes and aggregation.[253] The BDP nanoparticles remained unchanged 
through the lyophilization process without additional excipients (II, IV). In study III, 
trehalose was used to improve the stability of ITR nanoparticles during the freeze-dying. 
Long-term (3 months) stability studies for the freeze-dried ITR powders were performed at 
+ 40 °C/75% RH (relative humidity), and the dissolution profiles of the drug-nanoparticle 
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formulations before and after the storage were compared. The original samples released 
almost all their contents in the first 5 min, but for the stored BDP-HFBI samples it took some 
5 to 20 min more to reach plateau release values, which were also lower level than before 
storage. Storage had strong influence on BDP-HFBI samples and the drug release was much 
slower than in the beginning. The original (before storage) release rate could not be reached 
after storage period. These changes might be due to agglomeration of the stored particles. 
Trehalose had positive effects on the performance of the stored HFBI-DCBD-coated 
nanoparticles. The release rates were remained closer to the originals when trehalose was 
present during the storage.  
To improve stability and post-processing of the ITR and BDP nanoparticles, a NFC 
matrix was introduced to prevent aggregations of both HFBI and HFBI-DCBD coated 
nanoparticles (III, IV). Incorporation of the nanoparticles into the different NFC-matrices 
did not improve the stability of the BDP nanoparticles in suspension, except for the HFBI 
coated particles immobilized with bacterial cellulose (IV). They retained their size for more 
than 5 weeks. 
 However, the effect of CBDs was pronounced during the long-term storage of the ITR 
nanosuspensions (III). After ten month storage at +4 °C in an aqueous environment, 
morphology of the ITR nanoparticles coated with the ordinary HFBII was changed similarly 
to the morphology of the microcrystals, whereas the HFBI-DCBD coated particles remained 
unchanged.  
The long-term (3 months) stability studies for the freeze-dried ITR nanoparticles 
immobilized into the NFC were performed at + 40 °C/75% RH, and the dissolution profiles of 
the formulations were compared before and after the storage. Trehalose was used also here to 
improve the performance of freeze-drying. The ITR particles combined with NFC and 
trehalose were stabilized the most effectively during the freeze-drying and storage, resulting 
in the most uniform dissolution rates (III). Overall, the NFC may have a positive effect on the 
stabilization of the nanoparticles in suspension or during the freeze-drying.  
5.4.4 Drug release studies 
In drug delivery, porous matrices can be used as solid scaffolds in different 
formulations to carry the therapeutic agents. The drug delivery properties are largely 
influenced by the chemical structure and the textural properties of the matrices; the porosity, 
wettability, erosion and the surface area all have an effect on the drug release rates. The 
matrix has an influence on the release profile and, thus, for the bioavailability of the 
entrapped drug. Aerogels from nanofibrillar celluloses can be formed by removal of the water 
from the cellulose hydrogels (aqueous suspension) by freeze-drying.[201] In freeze-drying, 
the NFC network expands upon solvent evaporation. The dry network maintains to some 
extent its expanded, porous structure when vacuum is released and the network voids are 
filled with gas. By the definition, these aerogels are very porous solids formed by the 
replacement of liquid in a gel by gas.  
Therefore, nanofibrillar cellulose aerogels were evaluated besides as stabilizers for the 
nanoparticles during the freeze-drying (III), but also as a template for the controlled release 
(IV). Aerogels based on nanofibrillar celluloses with various characteristics (Table 9) were 
formed from bacterial cellulose, cellulose extracted from red pepper and quince seeds, as well 
as from TEMPO-oxidized cellulose. The microcrystalline cellulose (Avicel) was used as a 
reference material. 
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The specific target of the NFC aerogels was to be able to release the drug from the 
functionalized nanoparticles in a controlled manner by choosing and modifying the matrix 
formers. Controlled release of a drug from the matrix is important to ensure a constant drug 
concentration in vivo. The dissolution behavior of aerogels should be primarily dependent on 
the penetration of the medium into the matrix and the swelling properties of the porous 
matrix formed. The collapse of the freeze-dried cake may increase its density, which can lead 
to a decreased porosity and sublimation rates and, thus, retarded drying. However, the 
collapse doesn’t necessarily have an effect on the moisture content, stability or dissolution 
rate of the product, as shown previously [254], and here in the study IV. The rapid release of 
BDP into a medium from the nanoparticles incorporated into MCC or red pepper cellulose 
aerogels was comparable to the dissolution of BDP nanoparticles (Figure 12). These 
completely collapsed aerogels released BDP the fastest. The drug release from HFBI-DCBD 
coated particles was not retarded, although there should be stronger binding to the cellulose 
fibrils as attested earlier.[167] Freeze-dried aerogels which maintained the shape of the initial 
suspensions, without shrinkage or collapse, released the BDP slower and, thus, the 
nanoparticles immobilized into the bacterial cellulose, quince seed cellulose or TEMPO-
oxidized wood cellulose, showed sustained release of BDP (Figure 12).  
 
Figure 12 Drug release from two different cellulose aerogels. A) BDP was released fast 
from the nanoparticles immobilized into red pepper cellulose. B) Sustained 
BDP release was obtained from nanoparticles immobilized into quince seed 
cellulose matrix. Solid and open symbols represent HFBI and HFBI-DCBD 
coated nanoparticles, respectively. (IV) 
Based on the correlations between the thermal behavior and release rates of BDP, the 
interactions between the cellulose materials and the BDP-HFBI(-DCBD) nanoparticles 
affected the release rates of the drug together with the structured matrices. Therefore, the 
interactions in the matrix-nanoparticle composition are significant in the design of the NFC 
aerogels for controlled release drug delivery systems. Overall, the nanoparticles incorporated 
into the external biodegradable cellulose aerogels could release the drug in a controlled 
manner by the modulation of the matrix formers. The sustained drug release produced by 
these kinds of nanocomposite structures can be used to provide the prolonged blood 
concentrations of the drug compared to single nanoparticles which released their drug 
contents fast. 
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5.4.5 In vivo studies 
In study III, the hydrophobin coated drug nanoparticles were shown to improve the 
bioavailability and to enhance the drug exposure in vivo. A pharmacokinetic evaluation of the 
ITR nanosuspensions was carried out in rats. Plasma concentration versus time profiles of 
ITR and its active metabolite OH-ITR were studied after oral administration. Itraconazole 
microsuspension and cyclodextrin-based commercial Sporanox® solution were used as 
negative and positive control formulations, respectively. The nanosuspensions improved 
markedly the absorption of ITR. As indicated by the AUC values, the nanosuspensions 
provided about 20-fold increase in the absorption of ITR, when compared to the ITR 
microsuspension but did not alter the tmax values (Table 10). The improved oral absorption of 
ITR from the nanosuspensions could be explained by the improved dissolution rate with the 
decrease in particle size, due to the increased surface area, and the decreased diffusion layer 
thickness. Compared with the Sporanox® solution, the nanosuspensions had comparable 
pharmacokinetic values but showed less interindividual variability. The explanation could be 
that after the nanoparticles were dissolved in stomach, hydrophobins were capable of 
stabilizing ITR solution until the absorption took a place in small intestine. The AUC ratio of 
ITR and OH-ITR remained unchanged in all experiments, thus the metabolic activity of ITR 
was not affected. As shown by these experiments, the hydrophobin and NFC stabilized 
nanosuspension appears to be a very promising approach to enhance the oral bioavailability 
for BCS class II drugs. 
Table 10 Pharmacokinetic parameters of itraconazole (ITR) and hydroxyl-
itraconazole (OH-ITR) after oral delivery of itraconazole formulations. AUC 
and tmax of ITR and OH-ITR are expressed. Total AUC values are compared 
to Sporanox® (n = 4). Modified from reference III. 
 
Formulation AUC(ITR) 
 
[µg/ml h] 
tmax(ITR) 
 
[h] 
AUC(OH-ITR)  
 
[µg/ml h] 
tmax(OH-ITR) 
 
[h] 
∑AUC 
 
 [µg/ml h] 
AUC(∑ITR/ 
∑SPORANOX) 
[%] 
Sporanox® 0.49 4 (1-5) 2.32 5 (2-5) 2.81 100 
HFBI 0.55 4 (2-5) 3.05 10 (3-12) 3.61 128 
HFBI+NFC 0.56 3 (3-8) 2.78 3 (3-8) 3.33 119 
HFBI-DCBD+NFC 0.54 4 (3-8) 2.99 5 (3-8) 3.53 126 
ITR-suspension 0.04 3 (1-5) 0.18 5.5 (3-12) 0.22 8 
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6 Conclusions 
The electrospray apparatus was set-up for the production of poly(lactic acid) - drug 
nanoparticles. The main benefits of the electrospray method were options to affect the 
particle size as well as possibilities to entrap both hydrophobic and hydrophilic drugs into the 
nanoparticles. Therefore, the method is very suitable for the production of the polymeric 
drug nanoparticles for different purposes in a small scale.  
A precipitation method with hydrophobins as stabilizers enabled the successful 
preparation of small drug nanoparticles. The surface properties of the nanoparticles were 
modified by coupling two cellulose binding domains to the hydrophilic side of the 
hydrophobins. The fusion protein facilitated specific binding of drug nanoparticles into 
nanofibrillar cellulose. Long-term stability of the itraconazole nanoparticles in suspension 
was improved using specific binding to the nanofibrillar cellulose network and the 
nanoparticles were stable at least for 10 months.  
Nanofibrillar cellulose matrix enabled successful post-processing such as freeze-drying 
of ITR nanoparticles. Nanofibrillar cellulose aerogels with versatile characteristics could be 
used to release the drug in a controlled manner. Immediate or sustained release of BDP from 
the nanoparticles was obtained, depending on the structure and interactions formed by the 
nanoparticles and the cellulose matrix.  
As a summary of the thesis, biopolymer-based nanoparticles can increase and control 
the dissolution rate of the drugs and, thus, possibly improve the bioavailability of the drug 
compounds. They offer a competitive alternative to other drug delivery vehicles. In the case of 
polymer-based nanoparticles, the choice of the polymer is an issue and plays a key role in the 
formation of the particles, as well as in the physical stability of the system. Nanoparticles 
accompanied with a very diverse and versatile group of cellulose nanofibrils can be taken into 
consideration as advanced drug delivery systems.  
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